Sun Pharma enters into patent licensing agreement with Takeda
To commercialise Vonoprazan tablets in India
Sun Pharmaceutical Industries announced that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company (Takeda) to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name Voltapraz.
Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. Under the terms of this agreement, Takeda has granted Sun Pharma non-exclusive patent licensing rights for the commercialization of Vonoprazan in India.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content